{
  "trial_id": "NCT01767194",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, performance status (ECOG/Karnofsky/Lansky), prior treatments (chemotherapy, surgery, autologous stem cell transplant, radiotherapy, immunotherapy, retinoids), time since last treatment, measurable tumor status (MRI/CT scan), MIBG scan results, bone marrow involvement, creatinine clearance or serum creatinine, total bilirubin, serum glutamate pyruvate transaminase (SGPT/ALT), central nervous system function, cardiac function (shortening fraction/ejection fraction), pulmonary function, absolute neutrophil count (ANC), platelet count, prior anti-GD2 monoclonal antibody therapy, history of seizures, history of allergic reactions to anti-GD2 antibodies, presence of intercurrent illness, pregnancy status, lactation status, use of systemic steroids, use of anticonvulsants, history of myelodysplastic syndrome or other malignancies, symptoms of congestive heart failure, presence of uncontrolled infection, grade of diarrhea.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "performance status (ECOG/Karnofsky/Lansky)",
        "prior treatments (chemotherapy, surgery, autologous stem cell transplant, radiotherapy, immunotherapy, retinoids)",
        "time since last treatment",
        "measurable tumor status (MRI/CT scan)",
        "MIBG scan results",
        "bone marrow involvement",
        "creatinine clearance or serum creatinine",
        "total bilirubin",
        "serum glutamate pyruvate transaminase (SGPT/ALT)",
        "central nervous system function",
        "cardiac function (shortening fraction/ejection fraction)",
        "pulmonary function",
        "absolute neutrophil count (ANC)",
        "platelet count",
        "prior anti-GD2 monoclonal antibody therapy",
        "history of seizures",
        "history of allergic reactions to anti-GD2 antibodies",
        "presence of intercurrent illness",
        "pregnancy status",
        "lactation status",
        "use of systemic steroids",
        "use of anticonvulsants",
        "history of myelodysplastic syndrome or other malignancies",
        "symptoms of congestive heart failure",
        "presence of uncontrolled infection",
        "grade of diarrhea"
      ]
    },
    "processed-gen-response": "Age, gender, performance status (ECOG/Karnofsky/Lansky), prior treatments (chemotherapy, surgery, autologous stem cell transplant, radiotherapy, immunotherapy, retinoids), time since last treatment, measurable tumor status (MRI/CT scan), MIBG scan results, bone marrow involvement, creatinine clearance or serum creatinine, total bilirubin, serum glutamate pyruvate transaminase (SGPT/ALT), central nervous system function, cardiac function (shortening fraction/ejection fraction), pulmonary function, absolute neutrophil count (ANC), platelet count, prior anti-GD2 monoclonal antibody therapy, history of seizures, history of allergic reactions to anti-GD2 antibodies, presence of intercurrent illness, pregnancy status, lactation status, use of systemic steroids, use of anticonvulsants, history of myelodysplastic syndrome or other malignancies, symptoms of congestive heart failure, presence of uncontrolled infection, grade of diarrhea."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Performance Status (ECOG/Karnofsky/Lansky), Previous treatments (chemotherapy, radiotherapy, surgery, stem cell transplant), Disease status (recurrent, refractory, progressive), Measurable tumor presence, MIBG scan results, Bone marrow involvement, Peripheral absolute neutrophil count (ANC), Platelet count, Serum creatinine, Total bilirubin, Serum glutamate pyruvate transaminase (SGPT/ALT), Cardiac function (shortening fraction, ejection fraction), Pulmonary function (dyspnea, pulse oximetry), Coagulation status (Prothrombin time), Central nervous system function (seizure control, CNS toxicity),",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Performance Status (ECOG/Karnofsky/Lansky)",
        "Previous treatments (chemotherapy, radiotherapy, surgery, stem cell transplant)",
        "Disease status (recurrent, refractory, progressive)",
        "Measurable tumor presence",
        "MIBG scan results",
        "Bone marrow involvement",
        "Peripheral absolute neutrophil count (ANC)",
        "Platelet count",
        "Serum creatinine",
        "Total bilirubin",
        "Serum glutamate pyruvate transaminase (SGPT/ALT)",
        "Cardiac function (shortening fraction, ejection fraction)",
        "Pulmonary function (dyspnea, pulse oximetry)",
        "Coagulation status (Prothrombin time)",
        "Central nervous system function (seizure control, CNS toxicity)"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Performance Status (ECOG/Karnofsky/Lansky), Previous treatments (chemotherapy, radiotherapy, surgery, stem cell transplant), Disease status (recurrent, refractory, progressive), Measurable tumor presence, MIBG scan results, Bone marrow involvement, Peripheral absolute neutrophil count (ANC), Platelet count, Serum creatinine, Total bilirubin, Serum glutamate pyruvate transaminase (SGPT/ALT), Cardiac function (shortening fraction, ejection fraction), Pulmonary function (dyspnea, pulse oximetry), Coagulation status (Prothrombin time), Central nervous system function (seizure control, CNS toxicity)"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Performance Status (ECOG scores), Primary refractory disease, Relapsed disease, Progressive disease, Measurable tumor on MRI/CT scan, MIBG scan uptake, Bone marrow involvement, Peripheral absolute neutrophil count (ANC), Platelet count, Creatinine clearance or estimated radioisotope GFR, Serum creatinine, Total bilirubin, SGPT (ALT), Central nervous system function, Shortening fraction by ECHO, Ejection fraction by ECHO or gated radionuclide study, Prothrombin time (PT), Pulmonary function.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Performance Status (ECOG scores)",
        "Primary refractory disease",
        "Relapsed disease",
        "Progressive disease",
        "Measurable tumor on MRI/CT scan",
        "MIBG scan uptake",
        "Bone marrow involvement",
        "Peripheral absolute neutrophil count (ANC)",
        "Platelet count",
        "Creatinine clearance or estimated radioisotope GFR",
        "Serum creatinine",
        "Total bilirubin",
        "SGPT (ALT)",
        "Central nervous system function",
        "Shortening fraction by ECHO",
        "Ejection fraction by ECHO or gated radionuclide study",
        "Prothrombin time (PT)",
        "Pulmonary function"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Performance Status (ECOG scores), Primary refractory disease, Relapsed disease, Progressive disease, Measurable tumor on MRI/CT scan, MIBG scan uptake, Bone marrow involvement, Peripheral absolute neutrophil count (ANC), Platelet count, Creatinine clearance or estimated radioisotope GFR, Serum creatinine, Total bilirubin, SGPT (ALT), Central nervous system function, Shortening fraction by ECHO, Ejection fraction by ECHO or gated radionuclide study, Prothrombin time (PT), Pulmonary function."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, weight, height, performance status (ECOG scores), Karnofsky or Lansky score, primary tumor site, disease stage, prior therapy (including surgery, chemotherapy, autologous stem cell transplant, immunotherapy, radiotherapy, and retinoids), time since diagnosis, time since last therapy, presence of measurable tumor, MIBG scan results, catecholamine levels, creatinine clearance or estimated GFR, serum creatinine, total bilirubin, SGPT (ALT), CNS function, seizure history, echocardiogram or gated radionuclide study results, prothrombin time (PT), pulmonary function test results, diffusion capacity of the lung of carbon monoxide (DLCO).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "weight",
        "height",
        "performance status (ECOG scores)",
        "Karnofsky or Lansky score",
        "primary tumor site",
        "disease stage",
        "prior therapy (including surgery, chemotherapy, autologous stem cell transplant, immunotherapy, radiotherapy, and retinoids)",
        "time since diagnosis",
        "time since last therapy",
        "presence of measurable tumor",
        "MIBG scan results",
        "catecholamine levels",
        "creatinine clearance or estimated GFR",
        "serum creatinine",
        "total bilirubin",
        "SGPT (ALT)",
        "CNS function",
        "seizure history",
        "echocardiogram or gated radionuclide study results",
        "prothrombin time (PT)",
        "pulmonary function test results",
        "diffusion capacity of the lung of carbon monoxide (DLCO)"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, weight, height, performance status (ECOG scores), Karnofsky or Lansky score, primary tumor site, disease stage, prior therapy (including surgery, chemotherapy, autologous stem cell transplant, immunotherapy, radiotherapy, and retinoids), time since diagnosis, time since last therapy, presence of measurable tumor, MIBG scan results, catecholamine levels, creatinine clearance or estimated GFR, serum creatinine, total bilirubin, SGPT (ALT), CNS function, seizure history, echocardiogram or gated radionuclide study results, prothrombin time (PT), pulmonary function test results, diffusion capacity of the lung of carbon monoxide (DLCO)."
  }
}